Clinical trials: Hypercholesterolemia, completed
Hypercholesterolemia, Familial Hypercholesterolemia
Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan
The purpose of this post-marketing survey is to obtain real-world information on the safety and effectiveness of evolocumab in Japan.
- Trial name
- NCT02808403
- Testing
- No intervention
- Where
- 138 sites in Japan
- Volunteers
- 6,000 people
- Sponsor
- Amgen
Cardiovascular Diseases, Heart Diseases
Pawtucket Heart Health Program
To conduct a community-based research and demonstration project in cardiovascular disease prevention in the town of Pawtucket, Rhode Island.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Hypercholesterolemia, Hypertension
- Trial name
- NCT00005151
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Familial Hypercholesterolemia
Phase I Study of Ex Vivo Liver-Directed Gene Therapy for Familial Hypercholesterolemia
OBJECTIVES: I. Develop an approach for treating patients with homozygous familial hypercholesterolemia using gene therapy with autologous hepatocytes transduced with a normal low-density lipoprotein receptor gene.
- Trial name
- NCT00004809
- Testing
- gene therapy
- Volunteers
- 5 people
- Sponsor
- National Center for Research Resources (NCRR)
Hypercholesterolemia
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
Primary Objective: To evaluate the efficacy of alirocumab (75 or 150 milligrams [mg] depending on body weight [BW]), administered every 2 weeks (Q2W), on low-density lipoprotein cholesterol (LDL-C) levels at Week 12 of treatment…
- Trial name
- NCT03510715
- Testing
- Alirocumab SAR236553 (REGN727), Atorvastatin, Simvastatin
- Where
- 10 sites in Brazil, Canada and 8 more
- Volunteers
- 18 people
- Sponsor
- Sanofi
Pediatric Heterozygous Hypercholesterolemia
8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
To evaluate pharmacokinetics, pharmacodynamics, safety and tolerability of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia
- Trial name
- NCT00739999
- Testing
- Atorvastatin
- Where
- 3 sites in Canada, Greece and 1 more
- Volunteers
- 39 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Obesity, Overweight
Pediatric Preventative Health Screenings - Obesity and Family-Centered Outcomes
In 2012, an Expert Panel of the National Heart Lung and Blood Institute published guidelines on cardiovascular health and risk reduction in children; among these guidelines were screening recommendations for obesity and…
- Conditions
- Obesity, Overweight, Blood Pressure, Hypercholesteremia
- Trial name
- NCT02850224
- Testing
- Motivational interviewing to elicit PCO in pediatrics
- Where
- United States
- Volunteers
- 703 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Familial Hypercholesterolemia, Cholesterol, Elevated
Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)
The overall goal of this study is to promote awareness of Familial Hypercholesterolemia (FH). The investigators aim to enroll patients with suspected FH into the study and will randomize them to receive usual care or motivational…
- Conditions
- Familial Hypercholesterolemia, Cholesterol, Elevated, Genetic Disease
- Trial name
- ID-FH (NCT05238519)
- Testing
- Motivational interview (MI)
- Where
- 2 sites in United States
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Essentia Health
Familial Hypercholesterolaemia
An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia
This study is being carried out to see if the study medication, rosuvastatin, is effective in treating familial hypercholesterolaemia in children and adolescents, and to determine the long term (over 2 years) safety, tolerability…
- Trial name
- NCT01078675
- Testing
- rosuvastatin calcium
- Where
- 15 sites in United States, Belgium and 3 more
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
Cardiovascular Diseases, Heart Diseases
Primary Prevention of CHD Risk Factors Occurring in US
To evaluate the effectiveness of primary prevention of coronary heart disease risk factors by examining data from the National Health Examination Survey (NHES) and the National Health and Nutrition Examination Surveys (NHANES) to…
- Conditions
- Cardiovascular Diseases, Heart Diseases, Coronary Heart Disease Risk Reduction, Coronary Disease
- Trial name
- NCT00005495
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Familial Hypercholesterolemia, Adherence, Medication
The Use of Mobile Health Technology and Behavioral Economics to Encourage Adherence in Adolescents
Familial hypercholesterolemia (FH) affects over one million Americans and increases the risk of cardiovascular disease (CVD) by as much as 20-fold.
- Trial name
- NCT04458766
- Testing
- Monetary incentives
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Boston Children's Hospital
Hypercholesterolemia
Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)
This non-interventional longitudinal study is a follow-up of the Austrian Cholesterol Screening and Treatment project (ACT I), which assessed the cholesterol status, including achievement of the target levels applicable at that…
- Trial name
- ACT II (NCT01381679)
- Testing
- Ezetimibe
- Volunteers
- 1,682 people
- Sponsor
- Organon and Co
Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome
Pediatric Reporting of Adult-Onset Genomic Results
The Investigators will conduct a longitudinal, mixed-methods cohort study to assess primary and secondary psychosocial outcomes among MyCode adolescent participants and their parents, and health behaviors of children who received…
- Conditions
- Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Familial Hypercholesterolemia
- Trial name
- NCT03832985
- Testing
- Child(ren) receive an adult-onset result, Child(ren) received a pediatric-onset result, Control - Negative Result
- Where
- United States
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Geisinger Clinic
Familial Hypercholesterolemia, Polygenic Hypercholesterolaemia
Universal Familial Hypercholesterolemia Screening in Children
30 million individuals globally with undiagnosed familial hypercholesterolemia (FH) are at a substantial cardiovascular disease (CVD) risk, which could be normalized by early diagnosis and treatment.
- Trial name
- NCT04507984
- Testing
- Genetic analysis, Lipid levels measurement
- Where
- 2 sites in Germany, Slovenia
- Volunteers
- 17,000 people
- Sponsor
- University of Ljubljana, Faculty of Medicine
Hypercholesteremia
Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)
The purpose of this study was to assess the efficacy, safety, and tolerability of multiple doses of Gemcabene in patients with HoFH on stable, lipid-lowering therapy.
- Trial name
- NCT02722408
- Testing
- Gemcabene
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 8 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Familial Hypercholesterolemia
Cascade Genetic Testing of Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) is a frequent genetic disorder (1/200) associated with an increased risk of early-onset myocardial infarction.
- Trial name
- CATCH (NCT04419090)
- Testing
- web-based centralized service and message
- Where
- Switzerland
- Volunteers
- 379 people
- Sponsor
- Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
Cardiovascular Diseases, Heart Diseases
Evaluation of Cholesterol Education for At-Risk Children
To evaluate two educational programs that promoted the role of pediatric practices in lowering LDL cholesterol levels in 4-10 year old hypercholesterolemic children through dietary modification.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Hypercholesterolemia, Coronary Heart Disease Risk Reduction
- Trial name
- NCT00005718
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypercholesteremia
Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event
Observational study to investigate the use and efficacy of CRESTOR 5 mg in reaching LDL-C target goals in both statin naïve and statin treated primary and secondary prevention patients at high risk for a cardiovascular event.
- Trial name
- NCT00347217
- Where
- 215 sites in Netherlands
- Volunteers
- 3,840 people
- Sponsor
- AstraZeneca
Homozygous Familial Hypercholesterolemia
Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
The primary objectives of the study are: To evaluate the long-term safety and tolerability of evinacumab in patients with Homozygous Familial Hypercholesterolemia (HoFH) To evaluate the long-term safety and tolerability of…
- Trial name
- NCT03409744
- Testing
- evinacumab
- Where
- 38 sites in United States, Australia and 10 more
- Volunteers
- 116 people
- Sponsor
- Regeneron Pharmaceuticals
Hypercholesterolemia, Postmenopause
Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women
Estrogen therapy has been associated with reduced risk of coronary heart disease events in observational studies of postmenopausal women.
- Trial name
- NCT00001752
- Testing
- L-arginine, Estrogen
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Homozygous Familial Hypercholesterolemia
A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
The purpose of this study is to assess the safety, tolerability, and efficacy of ALN-PCSSC in participants with homozygous familial hypercholesterolemia.
- Trial name
- ORION-2 (NCT02963311)
- Testing
- ALN-PCSSC, Standard of Care
- Where
- 3 sites in United States, Netherlands and 1 more
- Volunteers
- 9 people
- Sponsor
- The Medicines Company